Egalet a/s Company Profile

02:01 EDT 18th March 2018 | BioPortfolio

Egalet a/s is focused on the development of innovative pharmaceutical products utilizing the Company’s proprietary, erosion-based, controlled-release technology, Egalet®, and a novel formulation system, Parvulet®, aimed at the pediatric market. Egalet’s product pipeline currently has four products in clinical development, two of which are entering late-stage pivotal studies in the cardiovascular and pain markets.


Lejrvej 37-41


Phone: 45 44 47 80 80
Fax: 45 44 47 24 25

News Articles [23 Associated News Articles listed on BioPortfolio]

Active-Investors: Wired News - Egalet Shares Positive Top-Line Results from Phase-3 Study of Egalet-002 in Patients with Chronic Low Back Pain

Stock Monitor: Enanta Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / November 30, 2017 / Active-Investors issued a free report on Egalet Corp. (NASDAQ: EGLT), which is readily accessible...

Egalet progressing second abuse-deterrent opioid med

Egalet says its share move up a hefty 38.55% after announcing positive top-line trial results from a…

Expanded label for Egalet's opioid pain drug gets tentative FDA nod

The FDA granted tentative approval to include a claim of intranasal abuse-deterrent on the label of Egalet's Arymo ER, or mor -More- 

Egalet Surges as Back Pain Drug Meets Goals in Phase III Trial

The study met its primary endpoint, which showed a statistically significant difference in average pain intensity from baseline to week 16 between the Egalet-002 and placebo treatment groups.

Egalet Receives FDA Tentative Approval for Expanded Label for ARYMO® ER (morphine sulfate) ...

ARYMO ER, developed using Egalet's proprietary Guardian™ Technology—a physical and chemical barrier approach to abuse deterrence without the use of an opioid antagonist—creating tablets that ...

Egalet receives FDA tentative approval for expanded label for ARYMO ER

Egalet, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced that the FDA has gra...

FDA Nod For Label Expansion Of Sutent, Egalet Flies, Double Blessing For Roche

Today's Daily Dose brings you news about Aerie's progress in phase II trial of glaucoma drug in Japan; phase III results of Egalet's pain pill; FDA approval of GlaxoSmithKline's COPD drug; expanded la...

Egalet Ltd. 2017 Q3 - Results - Earnings Call Slides

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [5 Associated Clinical Trials listed on BioPortfolio]

Effects of a Single Dose of Egalet® Morphine Combined With a Single Dose of Alcohol in Healthy Moderate Drinkers

The purpose of the study is to evaluate the pharmacokinetics of Egalet® morphine when administered with alcohol and compare to administration with water.

Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain

The purpose of this study is to evaluate the safety and tolerability of Egalet-002 in opioid-experienced patients with moderate-to-severe chronic noncancer pain.

Efficacy and Safety of Egalet-002 in Patients With Moderate-to-Severe Chronic Low Back Pain

The purpose of this study is to determine the analgesic efficacy of Egalet-002 twice daily (BID) in patients with moderate-to-severe chronic low back pain

A Efficacy and Safety Trial of Controlled Release (CR) Morphine in Cancer Patients

The purpose of the study is to determine the effect of Egalet® Morphine once daily compared to MST Continus twice daily on pain intensity and use of rescue medication for break through p...

A Study of Controlled-Release Carvedilol Compared to Immediate-Release Carvedilol in Patients With Primary Hypertension

The purpose of this study is to compare the efficacy of the Egalet® controlled release formulation to an immediate release Carvedilol tablet.

Companies [1 Associated Companies listed on BioPortfolio]

Egalet a/s

Egalet a/s is focused on the development of innovative pharmaceutical products utilizing the Company’s proprietary, erosion-based, controlled-release technology, Egalet®, and a novel formulation sy...

More Information about "Egalet a/s" on BioPortfolio

We have published hundreds of Egalet a/s news stories on BioPortfolio along with dozens of Egalet a/s Clinical Trials and PubMed Articles about Egalet a/s for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Egalet a/s Companies in our database. You can also find out about relevant Egalet a/s Drugs and Medications on this site too.

Quick Search


Relevant Topics

Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...

Pain is defined by the International Association for the Study of Pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage”. Some illnesses can be excruci...

Corporate Database Quicklinks

Searches Linking to this Company Record